<?xml version='1.0' encoding='utf-8'?>
<document id="31633365"><sentence text="Brivanib Exhibits Potential for Pharmacokinetic Drug-Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes." /><sentence text="Brivanib, a promising tyrosine kinase inhibitor, is currently undergoing advanced stages of clinical evaluation for solid tumor therapy"><entity charOffset="0-8" id="DDI-PubMed.31633365.s2.e0" text="Brivanib" /><entity charOffset="22-30" id="DDI-PubMed.31633365.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.31633365.s2.e0" e2="DDI-PubMed.31633365.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31633365.s2.e0" e2="DDI-PubMed.31633365.s2.e1" /></sentence><sentence text=" In this work, we investigated possible interactions of this novel drug candidate with ABC drug efflux transporters and cytochrome P450 (CYP450) drug-metabolizing enzymes that participate in cancer multidrug resistance (MDR) and pharmacokinetic drug-drug interactions (DDIs)" /><sentence text=" First, in accumulation experiments with various model substrates, we identified brivanib as an inhibitor of the ABCB1, ABCG2, and ABCC1 transporters" /><sentence text=" However, in subsequent combination studies employing 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide proliferation assays in both Madin-Darby canine kidney II (MDCKII) and A431 cellular models, only ABCG2 inhibition was revealed to be able to synergistically potentiate mitoxantrone effects"><entity charOffset="54-118" id="DDI-PubMed.31633365.s5.e0" text="3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide" /><entity charOffset="288-300" id="DDI-PubMed.31633365.s5.e1" text="mitoxantrone" /><pair ddi="false" e1="DDI-PubMed.31633365.s5.e0" e2="DDI-PubMed.31633365.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31633365.s5.e0" e2="DDI-PubMed.31633365.s5.e1" /></sentence><sentence text=" Advantageous to its possible use as MDR antagonist, brivanib's chemosensitizing properties were not impaired by activity of any of the MDR-associated ABC transporters, as observed in comparative viability assay in the MDCKII cell sublines" /><sentence text=" In incubation experiments with eight recombinant CYP450s, we found that brivanib potently inhibited CYP2C subfamily members and the CYP2B6 isoform" /><sentence text=" Finally, in induction studies, we demonstrated that brivanib upregulated ABCB1 and CYP1A2 messenger RNA levels in systemic cell models, although this interaction was not significantly manifested at a functional level" /><sentence text=" In conclusion, brivanib exhibits potential to cause clinically relevant pharmacokinetic DDIs and act as a modulator of ABCG2-mediated MDR"><entity charOffset="16-24" id="DDI-PubMed.31633365.s9.e0" text="brivanib" /></sentence><sentence text=" Our findings might be used as an important background for subsequent in vivo investigations and pave the way for the safe and effective use of brivanib in oncological patients" /><sentence text="" /></document>